Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparable outcomes after autologous hematopoietic cell transplantation in T-cell lymphoma regardless of pre-transplant response: A key finding in resource-limited countries.

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSebastián GaleanoRGRosanna De GiudaCOCristina Otero

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals progression-free survival of 59% in T-cell lymphoma patients receiving AHCT, suggesting potential benefits in resource-limited settings.

Key Points

  • Overall survival after AHCT reached 62% among patients with T-cell lymphoma who had undergone treatment.
  • Survival analysis showed promising five-year progression-free survival rates, particularly in anaplastic T-cell lymphoma cases.
  • Assessment relied on a retrospective study involving 93 patients, emphasizing potential benefits of AHCT in consolidating therapy.
  • Findings highlight the importance of AHCT in resource-limited countries where treatment options may be limited.

Cite This Study

Galeano et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da55https://doi.org/10.1182/blood-2025-2777
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hematopoietic stem cell transplantation in T-cell lymphomas: A promising strategy challenging poor prognosis2025
  2. 2Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India2025
  3. 3The role of hematopoietic stem cell transplantation in peripheral T-cell lymphoma not otherwise specified2025
  4. 4Second autologous transplantation remains a valid consolidation option in patients with relapsed multiple myeloma: A report from the Latin American bone marrow transplantation group2025
  5. 5Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP2025